Molecular Classification
G protein-coupled receptor, Receptor
Other Names
alpha-adrenergic receptor, α1 receptor, α2 receptor, alpha-1 adrenoceptor, alpha-2 adrenoceptor, alpha-adrenoceptor
Disease Roles
Cardiovascular disease (hypertension, heart failure, arrhythmia)Neuropathic painPsychiatric/neurological disorders (depression, ADHD, cognition)

Alpha-1 adrenergic receptor; Alpha-2 adrenergic receptor Overview

Alpha-1 and alpha-2 adrenergic receptors are two major families of G protein-coupled receptors that mediate the physiological actions of catecholamines (epinephrine and norepinephrine) in the peripheral and central nervous systems through distinct signaling pathways. - Alpha-1 adrenergic receptors are primarily postsynaptic and mediate smooth muscle contraction, vasoconstriction, and increased blood pressure, with roles in cognition and metabolism. Subtypes include α1A, α1B, and α1D[2][4][5][6][10]. - Alpha-2 adrenergic receptors are found both pre- and postsynaptically, especially as inhibitory auto-receptors in the CNS and periphery, reducing norepinephrine release and sympathetic outflow. They have subtypes α2A, α2B, and α2C[2][3][10]. Both families are pharmacological targets for a range of drugs used in cardiovascular, neurological, and pain indications. They are membrane glycoproteins possessing seven transmembrane domains, coupling respectively to Gq proteins (α1) and Gi proteins (α2), and are distinguished by their tissue distribution, downstream signaling, and pharmacological profiles[1][2][3][6][8][9][10].

Mechanism of Action

α1: Agonists cause vasoconstriction by activating Gq protein → increased IP3 and calcium signaling in smooth muscle α1 antagonists cause vasodilation by blocking this pathway α2: Agonists activate Gi protein, inhibit adenylate cyclase → reduced cAMP, inhibit norepinephrine release (presynaptic auto-receptor) α2 antagonists block inhibition, increasing norepinephrine release

Biological Functions

Signal transduction
Regulation of vascular tone/vasoconstriction
Neurotransmission modulation
Regulation of sympathetic nervous system
Inhibition/activation of norepinephrine release (α2: inhibitory auto-receptor; α1: stimulatory postsynaptic receptor)

Disease Associations

Cardiovascular disease (hypertension, heart failure, arrhythmia)
Neuropathic pain
Psychiatric/neurological disorders (depression, ADHD, cognition)
Inflammation (context-dependent)

Safety Considerations

  • orthostatic hypotension
  • syncope
  • dizziness
  • reflex tachycardia
  • hypertension
  • arrhythmia
  • headache
  • sedation
  • bradycardia
  • dry mouth
  • rebound hypertension upon withdrawal
  • anxiety
  • increased sympathetic activity

Interacting Drugs

prazosin
tamsulosin
doxazosin
phentolamine
phenylephrine
oxymetazoline
methoxamine
clonidine
dexmedetomidine
guanfacine
methyldopa
yohimbine
atipamezole

Associated Biomarkers

Biomarker
None in routine clinical use; changes in blood pressure, heart rate, and plasma norepinephrine may be indirect functional biomarkers